{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:24:44Z","timestamp":1773084284855,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,23]]},"DOI":"10.7759\/cureus.72222","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T18:48:45Z","timestamp":1729709325000},"source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Non-invasive Liver Fat Scoring Systems as Markers of Metabolic Dysfunction-Associated Liver Disease"],"prefix":"10.7759","author":[{"given":"Eunice S","family":"Thomson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash T","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheejamol V","family":"S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopalakrishna","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani N","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012, 55:2005-23. 10.1002\/hep.25762","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.07.012","article-title":"Drug-induced steatohepatitis","volume":"17","author":"Patel V","year":"2013","unstructured":"Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2013, 17:533-46, vii. 10.1016\/j.cld.2013.07.012","journal-title":"Clin Liver Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1753944717711379","article-title":"Metabolic syndrome: pathophysiology, management, and modulation by natural compounds","volume":"11","author":"Rochlani Y","year":"2017","unstructured":"Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017, 11:215-25. 10.1177\/1753944717711379","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/920983","article-title":"Prevalence of metabolic syndrome in urban India","volume":"2011","author":"Sawant A","year":"2011","unstructured":"Sawant A, Mankeshwar R, Shah S, et al.. Prevalence of metabolic syndrome in urban India. Cholesterol. 2011, 2011:920983. 10.1155\/2011\/920983","journal-title":"Cholesterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518793039","article-title":"Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups","volume":"46","author":"Mahale AR","year":"2018","unstructured":"Mahale AR, Prabhu SD, Nachiappan M, Fernandes M, Ullal S. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. J Int Med Res. 2018, 46:4447-54. 10.1177\/0300060518793039","journal-title":"J Int Med Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2014.07.008","article-title":"Non-alcoholic fatty liver disease, obesity and the metabolic syndrome","volume":"28","author":"Dietrich P","year":"2014","unstructured":"Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014, 28:637-53. 10.1016\/j.bpg.2014.07.008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00312-6","article-title":"Expanding public health responses to non-communicable diseases: the NAFLD model of India","volume":"8","author":"Prasad M","year":"2023","unstructured":"Prasad M, Sarin SK, Chauhan V. Expanding public health responses to non-communicable diseases: the NAFLD model of India. Lancet Gastroenterol Hepatol. 2023, 8:969-70. 10.1016\/S2468-1253(23)00312-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong L","year":"2022","unstructured":"Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022, 13:1087260. 10.3389\/fendo.2022.1087260","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6040086","article-title":"The role of vitamin E in the treatment of NAFLD","volume":"6","author":"Perumpail BJ","year":"2018","unstructured":"Perumpail BJ, Li AA, John N, et al.. The role of vitamin E in the treatment of NAFLD. Diseases. 2018, 6:10.3390\/diseases6040086","journal-title":"Diseases"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.06.015","article-title":"Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"44","author":"Sangouni AA","year":"2021","unstructured":"Sangouni AA, Orang Z, Mozaffari-Khosravi H. Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial. Clin Nutr ESPEN. 2021, 44:130-5. 10.1016\/j.clnesp.2021.06.015","journal-title":"Clin Nutr ESPEN"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue L","year":"2022","unstructured":"Xue L, Deng Z, Luo W, He X, Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol. 2022, 12:759306. 10.3389\/fcimb.2022.759306","journal-title":"Front Cell Infect Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15799","article-title":"Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: a population based study","volume":"37","author":"Liu Y","year":"2022","unstructured":"Liu Y, Liu S, Huang J, Zhu Y, Lin S. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: a population based study. J Gastroenterol Hepatol. 2022, 37:938-45. 10.1111\/jgh.15799","journal-title":"J Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10018-1370","article-title":"Gender differences in nonalcoholic fatty liver disease","volume":"12","author":"Nagral A","year":"2022","unstructured":"Nagral A, Bangar M, Menezes S, et al.. Gender differences in nonalcoholic fatty liver disease. Euroasian J Hepatogastroenterol. 2022, 12:S19-25. 10.5005\/jp-journals-10018-1370","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijge.2013.03.008","article-title":"Nonalcoholic fatty liver disease: prevalence, influence on age and sex, and relationship with metabolic syndrome and insulin resistance","volume":"7","author":"Cheng HY","year":"2013","unstructured":"Cheng HY, Wang HY, Chang WH, et al.. Nonalcoholic fatty liver disease: prevalence, influence on age and sex, and relationship with metabolic syndrome and insulin resistance. Int J Gerontol. 2013, 7:194-8. 10.1016\/j.ijge.2013.03.008","journal-title":"Int J Gerontol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.08.002","article-title":"Non-alcoholic fatty liver disease in lean individuals","volume":"1","author":"Albhaisi S","year":"2019","unstructured":"Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019, 1:329-41. 10.1016\/j.jhepr.2019.08.002","journal-title":"JHEP Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i5.1650","article-title":"Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index","volume":"21","author":"Pang Q","year":"2015","unstructured":"Pang Q, Zhang JY, Song SD, Qu K, Xu XS, Liu SS, Liu C. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol. 2015, 21:1650-62. 10.3748\/wjg.v21.i5.1650","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni G","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6:33. 10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2023.100161","article-title":"Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients from the Eastern region of India","volume":"12","author":"Sinha A","year":"2023","unstructured":"Sinha A, Bankura B. Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients from the Eastern region of India. Diabetes Epidemiol Manag. 2023, 12:100161. 10.1016\/j.deman.2023.100161","journal-title":"Diabetes Epidemiol Manag"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4137\/BMI.S38440","article-title":"Significance of HbA1c test in diagnosis and prognosis of diabetic patients","volume":"11","author":"Sherwani SI","year":"2016","unstructured":"Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016, 11:95-104. 10.4137\/BMI.S38440","journal-title":"Biomark Insights"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2017.03.006","article-title":"Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?","volume":"41","author":"Gutierrez-Buey G","year":"2017","unstructured":"Gutierrez-Buey G, N\u00fa\u00f1ez-C\u00f3rdoba JM, Llavero-Valero M, Gargallo J, Salvador J, Escalada J. Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?. Eur J Intern Med. 2017, 41:74-8. 10.1016\/j.ejim.2017.03.006","journal-title":"Eur J Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231204462","article-title":"HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population","volume":"51","author":"Zeng P","year":"2023","unstructured":"Zeng P, Cai X, Yu X, Huang L, Chen X. HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population. J Int Med Res. 2023, 51:3000605231204462. 10.1177\/03000605231204462","journal-title":"J Int Med Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-0986-7","article-title":"Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study","volume":"18","author":"Fan N","year":"2019","unstructured":"Fan N, Peng L, Xia Z, Zhang L, Song Z, Wang Y, Peng Y. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2019, 18:39. 10.1186\/s12944-019-0986-7","journal-title":"Lipids Health Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.163172","article-title":"Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes","volume":"19","author":"Sanyal D","year":"2015","unstructured":"Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015, 19:597-601. 10.4103\/2230-8210.163172","journal-title":"Indian J Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-020-01419-z","article-title":"Association between the alanine aminotransferase\/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study","volume":"19","author":"Zou Y","year":"2020","unstructured":"Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase\/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis. 2020, 19:245. 10.1186\/s12944-020-01419-z","journal-title":"Lipids Health Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/145754","article-title":"Diagnosis and evaluation of nonalcoholic fatty liver disease","volume":"2012","author":"Obika M","year":"2012","unstructured":"Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012, 2012:145754. 10.1155\/2012\/145754","journal-title":"Exp Diabetes Res"},{"key":"ref26","article-title":"Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease","volume":"74","author":"Vos B","year":"2011","unstructured":"Vos B, Moreno C, Nagy N, et al.. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg. 2011, 74:389-94.","journal-title":"Acta Gastroenterol Belg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/287794-comparison-of-non-invasive-liver-fat-scoring-systems-as-markers-of-metabolic-dysfunction-associated-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T18:48:47Z","timestamp":1729709327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/287794-comparison-of-non-invasive-liver-fat-scoring-systems-as-markers-of-metabolic-dysfunction-associated-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.72222","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}